SecBot SecBot
SECBOTREPLAY Home › Report › TRDA

TRDA · Entrada Therapeutics reported financial results for Q4 and full year…

Entrada Therapeutics, Inc. · 8-K filed Feb 26, 2026 at 07:04 ET

At the news

BEARISHIMPACT 6/10

8-K filed Feb 26, 2026 at 07:04 ET

Entrada Therapeutics reported financial results for Q4 and full year 2025, showing a significant decline in collaboration revenue and a shift from net income to a net loss compared to the prior year. The company highlighted clinical progress in its DMD and DM1 programs, including a positive DMC recommendation to advance the ELEVATE-44-201 study to a higher dose cohort. Cash runway is expected into Q3 2027 with $295.7 million in cash and marketable securities.

  • Collaboration revenue dropped to $25.4 million in 2025 from $210.8 million in 2024, primarily due to the substantial completion of VX-670 collaboration research activities in Q1 2025.
  • Net loss was $143.8 million for 2025 compared to net income of $65.6 million in 2024.
  • Cash, cash equivalents, and marketable securities were $295.7 million as of December 31, 2025, down from $420.0 million as of December 31, 2024.
  • The Independent Data Monitoring Committee recommended initiating Cohort 2 at a higher dose (12 mg/kg) in the ELEVATE-44-201 study without protocol modifications.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access